Illumina's third quarter was met with a negative market reaction. Management attributed the quarter's performance to strong clinical sequencing demand and robust placements of the NovaSeq X platform, which CEO Jacob Thaysen described as fueling both margin and earnings expansion. However, the company acknowledged continued weakness in research and applied markets, offset by the momentum in clinical applications and new product introductions like the BioInsight software suite.
Is now the time to buy ILMN? Find out in our full research report (it’s free for active Edge members).
Illumina (ILMN) Q3 2026 highlights:
- Revenue $1.17 billion vs S&P analysts’ estimates of $1.15 billion (7.6% year-on-year growth, 1.1% beat)
- Adjusted EPS $1.44 vs S&P analysts’ estimates of $1.36 (6.1% beat)
- Adjusted operating income $292 million vs analyst estimates of $276.8 million (25% margin, 5.5% beat)
- Revenue guidance The company slightly lifted its revenue guidance for the full year to $4.65 billion at the midpoint from $4.62 billion
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $5.43 at the midpoint, a 1.4% increase
- Operating margin 26.2%, up from 20.9% in the same quarter last year
- Organic revenue rose 4.8% year on year (miss)
- Market capitalization $35.63 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from Illumina’s Q3 earnings call
- Tycho Peterson (Jefferies): Asked if clinical consumables growth reflected one-time stocking orders and whether the current growth rates are sustainable. CEO Jacob Thaysen emphasized continued strong demand and projected mid-teens growth, dismissing significant quarter-specific distortions.
- Vijay Kumar (Evercore ISI): Inquired about whether elevated NovaSeq X placements could become a headwind next year and how that might be offset. Thaysen stated that strong placements will continue to drive consumables growth and that the long-term strategy remains intact.
- Doug Schenkel (UBS): Questioned if recent NovaSeq X demand was a pull-forward of future orders or indicative of sustained demand. Thaysen responded that the placement pace reflects normal business, with no evidence of demand being pulled forward.
- Dan Leonard (RBC): Sought clarity on when BioInsight and other AI-driven offerings will become financially material. Thaysen and CFO Ankur Dhingra indicated these products could contribute visibly to growth by 2027.
- Casey Woodring (JPMorgan): Asked about geopolitical risks in China and the impact of regulatory uncertainties. Thaysen reaffirmed commitment to the Chinese market and noted improving relationships with regulators but acknowledged ongoing risks.
Catalysts in upcoming quarters
In coming quarters, the StockStory team will closely watch (1) the pace of clinical sequencing growth, especially the adoption of new diagnostic tests and oncology applications; (2) further expansion and utilization of the NovaSeq X installed base, which underpins consumables revenue; and (3) progress in monetizing AI-driven data initiatives like the Billion Cell Atlas and BioInsight platform. Developments in China and regulatory outcomes will also be critical to track.
Illumina currently trades at $235.59, down from $290.06 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).
Our favorite stocks right now
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
